These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 14711304)

  • 1. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
    Wendt MD; Rockway TW; Geyer A; McClellan W; Weitzberg M; Zhao X; Mantei R; Nienaber VL; Stewart K; Klinghofer V; Giranda VL
    J Med Chem; 2004 Jan; 47(2):303-24. PubMed ID: 14711304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.
    Wendt MD; Geyer A; McClellan WJ; Rockway TW; Weitzberg M; Zhao X; Mantei R; Stewart K; Nienaber V; Klinghofer V; Giranda VL
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3063-8. PubMed ID: 15149645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
    Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
    J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
    Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
    J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
    West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
    Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
    J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.
    Bruncko M; McClellan WJ; Wendt MD; Sauer DR; Geyer A; Dalton CR; Kaminski MA; Weitzberg M; Gong J; Dellaria JF; Mantei R; Zhao X; Nienaber VL; Stewart K; Klinghofer V; Bouska J; Rockway TW; Giranda VL
    Bioorg Med Chem Lett; 2005 Jan; 15(1):93-8. PubMed ID: 15582418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity.
    Grembecka J; Mucha A; Cierpicki T; Kafarski P
    J Med Chem; 2003 Jun; 46(13):2641-55. PubMed ID: 12801228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
    Renatus M; Bode W; Huber R; Stürzebecher J; Stubbs MT
    J Med Chem; 1998 Dec; 41(27):5445-56. PubMed ID: 9876114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.
    Lucas S; Heim R; Negri M; Antes I; Ries C; Schewe KE; Bisi A; Gobbi S; Hartmann RW
    J Med Chem; 2008 Oct; 51(19):6138-49. PubMed ID: 18763754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
    Bhongade BA; Gouripur VV; Gadad AK
    Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator.
    Yang SQ; Craik CS
    J Mol Biol; 1998 Jun; 279(4):1001-11. PubMed ID: 9642077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity.
    Sieńczyk M; Oleksyszyn J
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2886-90. PubMed ID: 16546384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
    Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
    J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species specificity of amidine-based urokinase inhibitors.
    Klinghofer V; Stewart K; McGonigal T; Smith R; Sarthy A; Nienaber V; Butler C; Dorwin S; Richardson P; Weitzberg M; Wendt M; Rockway T; Zhao X; Hulkower KI; Giranda VL
    Biochemistry; 2001 Aug; 40(31):9125-31. PubMed ID: 11478879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.
    Nienaber VL; Davidson D; Edalji R; Giranda VL; Klinghofer V; Henkin J; Magdalinos P; Mantei R; Merrick S; Severin JM; Smith RA; Stewart K; Walter K; Wang J; Wendt M; Weitzberg M; Zhao X; Rockway T
    Structure; 2000 May; 8(5):553-63. PubMed ID: 10801494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
    Andersen LM; Wind T; Hansen HD; Andreasen PA
    Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.